Fig. 2
- ID
- ZDB-FIG-220718-34
- Publication
- Lubanska et al., 2022 - Impairing proliferation of glioblastoma multiforme with CD44+ selective conjugated polymer nanoparticles
- Other Figures
- All Figure Page
- Back to All Figure Page
HA-CPNs Demonstrate Selective Uptake by CD44 Enriched U-251 MG Cells as well as GBM Patient-derived Cells. (A) Representative image of cells stained with anti-CD44 antibody and treated with 24 HA-CPNs/cell or vehicle control (Control); scale bar: 25 μm; (B) Flowcytometry analysis of U-251 MG cells stained with anti-CD44 antibody and treated with 24, 48, 96 HA-CPNs/cell or vehicle control (Control). Cells positive for HA-CPNs graphed as % of cells positive (CD44 +) and/or negative (CD44-) for the antibody stain; (C) Flowcytometry analysis of HA- CPN positive U-251 MG cells in FACS- derived CD44 + and CD44- populations treated with 12, 24, 36 HA-CPNs/cell graphed as % of the population tested; (D) GBM patient- derived cultures (HF3035, HF3016, HF3077, HF3253, HF2303) tested for CD44-selective HA-CPN uptake and quantified as % of CD44 + cells relative to the % uptake in CD44- cells. Data shown as mean ± s.d, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001; Student’s t-test. |